VANCOUVER, May 20 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in the development of receptor targeted fusion proteins, today announced that preliminary data from the Phase 1 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH), will be presented at the 2008 Annual Meeting of the American Urological Association (AUA). The 2008 AUA Meeting is the world’s largest gathering of urology professionals and will take place at the Orange County Convention Center in Orlando, Florida.
